ELACESTRANT
AssetAlso called RAD1901, RAD-1901
Selectively binds estrogen receptor alpha, antagonizing its signaling and promoting its degradation.
- Stage
- Approved
- Modality
- Small molecule
- Target
- ESR1
- 6
- Indications
- 37
- Trials
- 2
- Developers
Approved by the FDA on Jan 27, 2023 (NDA217639). 2 approvals stand. FDA
Indications
6Er-positive, HER2-negative, ESR1-mutated advanced or metastatic breast cancer
Approved, FDA
Advanced or Metastatic Breast Cancer
Approved, FDA
Breast neoplasm
Approved, EMA
3 more
In the full profile
- Target and mechanism1
- Owner and partners2
- Trials37
- Evidence for its targets1
- Competitors12
- Signals5
Every asset’s record: target, stage, trials and the evidence behind it.